Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension

被引：0
|
作者：
Sinclair, Rodney [1 ]
Thaci, Diamant [2 ]
Vender, Ronald [3 ]
de Rie, Menno [4 ]
Conrad, Curdin [5 ]
Soung, Jennifer [6 ]
Strober, Bruce [7 ,8 ]
Wang, Maggie [9 ]
Cross, Nancy [10 ]
Deherder, Delphine [9 ]
Gomez, Natalie Nunez [11 ]
Gottlieb, Alice B. [12 ]
机构：
[1] Sinclair Dermatol, East Melbourne, Vic, Australia
[2] Univ Lubeck, Lubeck, Germany
[3] Dermatrials Res Inc, Hamilton, ON, Canada
[4] Univ Amsterdam, Dept Dermatol, Med Ctr, Amsterdam, Netherlands
[5] Lausanne Univ Hosp, Dept Dermatol, Lausanne, Switzerland
[6] Southern Calif Dermatol, Santa Ana, CA USA
[7] Yale Univ, New Haven, CT USA
[8] Cent Connecticut Dermatol Res, Cromwell, CT USA
[9] UCB Pharma, Brussels, Belgium
[10] UCB, Morrisville, NC USA
[11] UCB Pharma, Monheim, Germany
[12] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [41] Long-term efficacy and safety of ustekinumab in patients with moderate to severe psoriasis through 5 years of follow-up: results from the PHOENIX 1 long-term extension
    Kimball, A. B.
    Papp, K. A.
    Wasfi, Y.
    Chan, D.
    Bissonnette, R.
    Sofen, H.
    Yeilding, N.
    Li, S.
    Szapary, P. O.
    Gordon, K. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 : 63 - 64
  • [42] Bimekizumab in patients with moderate to severe plaque psoriasis: Injection site reactions through two years of the BE RADIANT phase 3b trial and open-label extension with one-year comparison to secukinumab
    Soung, Jennifer
    Rosmarin, David
    Ferrer, Anna Lopez
    Lain, Edward
    Rich, Phoebe
    White, Katy
    Staelens, Fabienne
    Szilagyi, Balint
    Deherder, Delphine
    Magnolo, Nina
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB128 - AB128
  • [43] Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study
    Wallace, D. J.
    Hobbs, K.
    Clowse, M. E. B.
    Petri, M.
    Strand, V.
    Pike, M.
    Merrill, J. T.
    Leszczynski, P.
    Neuwelt, C. M.
    Jeka, S.
    Houssiau, F.
    Keiserman, M.
    Ordi-Ros, J.
    Bongardt, S.
    Kilgallen, B.
    Galateanu, C.
    Kalunian, K.
    Furie, R.
    Gordon, C.
    ARTHRITIS CARE & RESEARCH, 2016, 68 (04) : 534 - 543
  • [44] Long-term Safety and Efficacy of Etanercept in Patients With Psoriasis: An Open-label Study
    Leonardi, Craig
    Strober, Bruce
    Gottlieb, Alice B.
    Elewski, Boni E.
    Ortonne, Jean-Paul
    van de Kerkhof, Peter
    Chiou, Chiun-Fang
    Dunn, Meleana
    Jahreis, Angelika
    JOURNAL OF DRUGS IN DERMATOLOGY, 2010, 9 (08) : 928 - 937
  • [45] Safety of efalizumab therapy in patients with moderate to severe psoriasis - An open-label extension of a phase IIIb trial
    Hamilton, Tiffani
    Menter, Alan
    Caro, Ivor
    Compton, Peter
    Sobell, Jeffrey
    Papp, Kim A.
    DRUG SAFETY, 2008, 31 (08) : 715 - 726
  • [46] Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial
    Grossman, J
    Smith, LJ
    Wilson, AM
    Thyrum, PT
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1999, 82 (04) : 361 - 369
  • [47] Long-Term Safety and Efficacy of Voxelotor for Patients with Sickle Cell Disease: Results from an Open-Label Extension of the Phase 3 HOPE Trial
    Achebe, Maureen
    Hassab, Hoda
    Alkindi, Salam
    Brown, R. Clark Clark
    Telfer, Paul
    Biemond, Bart J.
    Gordeuk, Victor R.
    Lipato, Thokozeni
    Tonda, Margaret
    Gray, Sarah
    Howard, Joanna
    BLOOD, 2021, 138
  • [48] Long term efficacy and safety of ustekinumab in patients with moderate to severe psoriasis through 5 years of follow-up: results from the PHOENIX 1 long-term extension
    Papp, K.
    Kimball, A.
    Wasfi, Y.
    Chan, D.
    Bissonnette, R.
    Sofen, H.
    Yeilding, N.
    Li, S.
    Szapary, P.
    Gordon, K.
    JOURNAL OF DERMATOLOGY, 2012, 39 : 239 - 240
  • [49] Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease: Results From the One-Year SEQUENCE Open-Label Long-Term Extension
    Peyrin-Biroulet, L.
    Atreya, R.
    Danese, S.
    Lindsay, J. O.
    Chapman, J. C.
    Anschutz, T.
    Huang, X.
    Zambrano, J.
    Platt, A.
    Joshi, N.
    Cross, R. K.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1407 - i1409
  • [50] Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) trial up to 4 years
    Wollenberg, Andreas
    Soong, Weily
    Goooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB106 - AB106
12345